Media headlines about TrovaGene (NASDAQ:TROV) have been trending positive recently, according to Accern. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. TrovaGene earned a coverage optimism score of 0.30 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 45.6485159872608 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:

TrovaGene (NASDAQ TROV) opened at 0.8285 on Friday. TrovaGene has a 12-month low of $0.61 and a 12-month high of $5.19. The firm’s 50-day moving average price is $0.94 and its 200-day moving average price is $1.13. The company’s market cap is $30.88 million.

A number of brokerages have weighed in on TROV. Maxim Group set a $4.00 price objective on TrovaGene and gave the company a “buy” rating in a research note on Thursday, July 6th. Cantor Fitzgerald restated an “overweight” rating on shares of TrovaGene in a research note on Tuesday, August 8th.

COPYRIGHT VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/27/trovagene-trov-getting-favorable-media-coverage-study-shows.html.

About TrovaGene

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Insider Buying and Selling by Quarter for TrovaGene (NASDAQ:TROV)

Receive News & Stock Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related stocks with our FREE daily email newsletter.